Vasorum

Scott Kraus

CEO Vasorum

Scott Kraus has experience in executive management roles and has been a key driver in building shareholder value with large and small start-up medical device companies for 30 + years. Most recently, Scott served as the Chief Operating Officer at Cardio Flow, Inc. where he helped gain FDA clearance of the Freedom Flow® atherectomy platform and conduct a limited market release. 

Prior to that Scott was Zone General Manager with Abiomed, where he was responsible for driving product adoption of the Impella® pVAD systems, which was recently acquired by Johnson & Johnson in for $16.6B.

Prior to this, he worked for a series of start-ups: Cardiovascular Systems, Inc. (CSI) (acquired by Abbott), Intact Vascular (acquired by Philips), and  Intersect ENT (acquired by Medtronic), where he gained strategic and tactical experience launching and driving product launches of disruptive technologies in newly created markets, ranging from orbital atherectomy systems and drug-eluting stents to implantable cardiac rhythm devices.

Most notably, Scott joined CSI as a Product Manager in Germany, where he worked with key opinion leaders to gain knowledge and preparation for developing the US go-to-market strategy . He subsequently served as VP of Sales at CSI, where he helped build out an industry recognized peripheral and coronary team of ~135-person commercial team that generated $80M in revenue. During his tenure there, he was instrumental in driving strategic and tactical plans for commercial execution that resulted in achieving market leadership. At Intact Vascular, he held the role of  VP of Sales and Market Development, where he worked closely with the CEO to raise a $15M Series A, which was utilized to fund the TOBA study in Europe, paving the US regulatory path.

Scott has worked for a combination of commercial and clinical-stage companies over the course of his career, and his scope of influence spans commercial, market development and cross functional collaboration with finance, clinical and regulatory teams.

Earlier in Scott’s career he worked at Boston Scientific, C.R. Bard, and Guidant in the coronary, peripheral, and vascular surgery markets, gaining experience in creating new markets,  launching interventional devices and procedural expansion. Scott holds a B.S. in Finance from Villanova University and an MBA from Saint Joseph’s University.

Jim Coleman MD

COO & CMO Vasorum

Dr. Jim Coleman is the co-founder and COO of Vasorum. He has extensive experience in medical device development and in the sale and licensing of numerous technologies. Prior to his experience with start-up companies, he spent 7 years as Senior International Medical Director for the Surgical Division of American Cyanamid Corporation, American Home Corporations U.S.A., and Tyco (Covidien). Dr. Coleman holds multiple issued worldwide medical device patents, he is a General and Vascular Surgeon by training and is a Fellow of the Royal College of Surgeons, Ireland.

David Gunther

VP Sales & Marketing, Vasorum

David J Gunther BSc has extensive experience in cardiovascular medical device commercialization. He has held sales, sales management, and training positions at four start-up companies from commercialization to successful exit: TVA Medical (acquired by Bard), AccessClosure (acquired by Cardinal Health), Foxhollow (acquired by Medtronic), and Coalescent Surgical (acquired by Medtronic). He has also had sales positions at Ethicon Endo-Surgery and Pfizer. David has a BSc in Biochemisty from University of Notre Dame.